Optimizing vancomycin dosing in septic patients
Phase 2
Recruiting
- Conditions
- Sepsis.Sepsis, unspecified
- Registration Number
- IRCT20100228003449N24
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Patients with sepsis
Patients with augmented renal clearance
Patients with vancomycin indication
Serum creatinine less than 1.3 mg/dl
Exclusion Criteria
Age less than 18 years old and more than 75 years old
Receiving concomitant nephrotoxic agents
Pregnancy
Patients with vancomycin contraindications
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Access vancomycin target concentration. Timepoint: Days 2-5. Method of measurement: Chemiluminescent immunoassay (CLIA).;Clearance of systemic inflammatory response syndrome. Timepoint: Daily. Method of measurement: Evaluating vital signs, hemodynamic parameters and laboratory tests.
- Secondary Outcome Measures
Name Time Method Vancomycin induced nephrotoxicity. Timepoint: Daily measurement of serum creatinine. Method of measurement: 0.5 mg/dl or 50% increase in serum creatinine from the baseline value.